TY - JOUR
T1 - Research design considerations for chronic pain prevention clinical trials
T2 - IMMPACT recommendations
AU - Gewandter, Jennifer S
AU - Dworkin, Robert H
AU - Turk, Dennis C
AU - Farrar, John T
AU - Fillingim, Roger B
AU - Gilron, Ian
AU - Markman, John D
AU - Oaklander, Anne Louise
AU - Polydefkis, Michael J
AU - Raja, Srinivasa N
AU - Robinson, James P
AU - Woolf, Clifford J
AU - Ziegler, Dan
AU - Ashburn, Michael A
AU - Burke, Laurie B
AU - Cowan, Penney
AU - George, Steven Z
AU - Goli, Veeraindar
AU - Graff, Ole X
AU - Iyengar, Smriti
AU - Jay, Gary W
AU - Katz, Joel
AU - Kehlet, Henrik
AU - Kitt, Rachel A
AU - Kopecky, Ernest A
AU - Malamut, Richard
AU - McDermott, Michael P
AU - Palmer, Pamela
AU - Rappaport, Bob A
AU - Rauschkolb, Christine
AU - Steigerwald, Ilona
AU - Tobias, Jeffrey
AU - Walco, Gary A
N1 - Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain.
PY - 2021
Y1 - 2021
N2 - Although certain risk factors can identify individuals who are most likely to develop chronic pain, few interventions to prevent chronic pain have been identified. To facilitate the identification of preventive interventions, an IMMPACT meeting was convened to discuss research design considerations for clinical trials investigating the prevention of chronic pain. We present general design considerations for prevention trials in populations that are at relatively high risk for developing chronic pain. Specific design considerations included subject identification, timing and duration of treatment, outcomes, timing of assessment, and adjusting for risk factors in the analyses. We provide a detailed examination of 4 models of chronic pain prevention (ie, chronic postsurgical pain, postherpetic neuralgia, chronic low back pain, and painful chemotherapy-induced peripheral neuropathy). The issues discussed can, in many instances, be extrapolated to other chronic pain conditions. These examples were selected because they are representative models of primary and secondary prevention, reflect persistent pain resulting from multiple insults (ie, surgery, viral infection, injury, and toxic or noxious element exposure), and are chronically painful conditions that are treated with a range of interventions. Improvements in the design of chronic pain prevention trials could improve assay sensitivity and thus accelerate the identification of efficacious interventions. Such interventions would have the potential to reduce the prevalence of chronic pain in the population. Additionally, standardization of outcomes in prevention clinical trials will facilitate meta-analyses and systematic reviews and improve detection of preventive strategies emerging from clinical trials.
AB - Although certain risk factors can identify individuals who are most likely to develop chronic pain, few interventions to prevent chronic pain have been identified. To facilitate the identification of preventive interventions, an IMMPACT meeting was convened to discuss research design considerations for clinical trials investigating the prevention of chronic pain. We present general design considerations for prevention trials in populations that are at relatively high risk for developing chronic pain. Specific design considerations included subject identification, timing and duration of treatment, outcomes, timing of assessment, and adjusting for risk factors in the analyses. We provide a detailed examination of 4 models of chronic pain prevention (ie, chronic postsurgical pain, postherpetic neuralgia, chronic low back pain, and painful chemotherapy-induced peripheral neuropathy). The issues discussed can, in many instances, be extrapolated to other chronic pain conditions. These examples were selected because they are representative models of primary and secondary prevention, reflect persistent pain resulting from multiple insults (ie, surgery, viral infection, injury, and toxic or noxious element exposure), and are chronically painful conditions that are treated with a range of interventions. Improvements in the design of chronic pain prevention trials could improve assay sensitivity and thus accelerate the identification of efficacious interventions. Such interventions would have the potential to reduce the prevalence of chronic pain in the population. Additionally, standardization of outcomes in prevention clinical trials will facilitate meta-analyses and systematic reviews and improve detection of preventive strategies emerging from clinical trials.
KW - Chemotherapy-induced peripheral neuropathy
KW - Chronic low back pain
KW - Chronic postsurgical pain
KW - Postherpetic neuralgia
KW - Prevention trial design
KW - Risk factors
UR - http://www.scopus.com/inward/record.url?scp=85124612848&partnerID=8YFLogxK
U2 - 10.1097/PR9.0000000000000895
DO - 10.1097/PR9.0000000000000895
M3 - Review
C2 - 33981929
SN - 2471-2531
VL - 6
JO - Pain Reports
JF - Pain Reports
IS - 1
M1 - e895
ER -